Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck (MRK) Reports In-Line Q4; Guides In-Line
February 2, 2017 6:47 AM ESTMerck (NYSE: MRK) reported Q4 EPS of $0.89, versus the consensus of $0.89. Revenue for the quarter came in at $10.1 billion, versus $10.22 billion consensus.
GUIDANCE:
Merck sees FY2017 EPS of $3.72-$3.87, versus the consensus of $3.85.
For earnings history and earnings-related data on Merck (MRK) click here.
... More